What are the side effects of trimethoprim‑sulfamethoxazole (TMP‑SMX)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Side Effects of Trimethoprim-Sulfamethoxazole (TMP-SMX)

The most common side effects of TMP-SMX are dermatologic reactions (rash, urticaria) and hematologic abnormalities (leukopenia, thrombocytopenia), while rare but serious reactions include Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, and blood dyscrasias. 1, 2

Common Side Effects

Dermatologic Reactions

  • Mild cutaneous reactions occur in approximately 16% of children receiving prophylactic TMP-SMX, presenting as erythematous maculopapular rash or urticaria 3
  • In HIV-infected children, 82% of adverse reactions are cutaneous, with only 15% experiencing any adverse reaction overall 3
  • Important distinction: HIV-infected adults experience significantly higher rates (40-65%) of adverse reactions compared to children 3

Hematologic Abnormalities

  • Leukopenia and thrombocytopenia are the principal hematologic reactions 3
  • Incidence varies widely: from <0.1% in hospitalized patients to 12-34% in outpatient therapeutic courses 3
  • Hematologic toxicity may be increased when combined with zidovudine due to additive bone marrow suppression 3
  • Monitoring requirement: Complete blood counts with differential and platelet count should be performed at initiation and monthly intervals 3

Gastrointestinal Effects

  • Nausea, vomiting, and anorexia are common 2
  • Abdominal pain and diarrhea occur frequently 2

Serious but Rare Side Effects

Life-Threatening Dermatologic Reactions

  • Stevens-Johnson syndrome and exfoliative dermatitis occur in approximately 1/200,000 courses of therapy 3
  • Toxic epidermal necrolysis is rare but potentially fatal 1, 2
  • If these occur, TMP-SMX must be permanently discontinued 3

Severe Hematologic Reactions

  • Fatal reactions occur in <1/100,000 children 3
  • Agranulocytosis, aplastic anemia, and megaloblastic anemia are rare but documented 1, 2
  • Hemolytic anemia can occur in patients with G6PD deficiency, though rarely reported 3

Hepatotoxicity

  • Fulminant hepatic necrosis is rare but potentially fatal 1, 2
  • Hepatitis with cholestatic jaundice and hepatic necrosis can occur 2
  • Elevation of serum transaminases and bilirubin 2
  • Recent case reports document severe acute liver injury with both hepatocellular and cholestatic patterns 4, 5

Renal Toxicity

  • Renal failure, interstitial nephritis, and crystalluria 2
  • BUN and serum creatinine elevation 2
  • Risk factors: Cardiovascular disease is an independent risk factor for creatinine elevation 6
  • Adequate fluid intake is essential to prevent crystalluria and stone formation 2

Metabolic Abnormalities

  • Hyperkalemia is particularly concerning in AIDS patients and those with renal insufficiency 1, 2
  • Metabolic acidosis, especially in critically ill patients 6
  • Hypoglycemia (rare), particularly in non-diabetic patients with renal dysfunction, liver disease, or malnutrition 2

Neuropsychiatric Effects

  • Aseptic meningitis (rare) 2, 7
  • Acute psychosis and hallucinations, even in immunocompetent patients 8
  • Peripheral neuritis, ataxia, vertigo, tinnitus, headache 2
  • Convulsions, depression, hallucinations 2

Respiratory Complications

  • Acute respiratory failure: FDA warning issued for adolescents and young adults aged 10-25 years 9
  • 30-day risk of hospital visit with acute respiratory failure is 2.79-2.85 times higher compared to amoxicillin or cephalosporins 9
  • Cough, shortness of breath, and pulmonary infiltrates 2

Other Serious Reactions

  • Anaphylaxis 2
  • Pseudomembranous enterocolitis 2
  • Pancreatitis 2
  • Rhabdomyolysis (isolated cases, mainly in AIDS patients) 2

Special Population Considerations

AIDS Patients

  • Dramatically higher incidence of side effects, particularly rash, fever, leukopenia, and elevated aminotransferases 1, 2
  • Hyperkalemia appears increased in this population 1
  • Adverse effects are generally less severe with prophylactic dosing versus treatment dosing 1

Neonates

  • Contraindicated due to concerns about bilirubin displacement and rapidly changing drug metabolism during the first month of life 3

Patients with Renal or Cardiac Disease

  • Increased risk of hyperkalemia, metabolic acidosis, and renal dysfunction 6, 10
  • Cardiovascular disease is an independent risk factor for creatinine elevation 6

Management of Adverse Reactions

Mild to Moderate Reactions

  • For mild rash: temporarily discontinue and restart when resolved 1
  • Some patients can be successfully desensitized using gradual dose escalation 3
  • If desensitization is performed, daily dosing is required to prevent serious reactions upon reintroduction 3

Severe Reactions Requiring Permanent Discontinuation

  • Anaphylaxis 3
  • Stevens-Johnson syndrome 1, 3
  • Urticarial rash 1
  • Hypotension 3

Drug Interactions Increasing Toxicity Risk

  • Teicoplanin: associated with ALT elevation 6
  • Colistin-echinocandin combination: associated with thrombocytopenia 6
  • Thiazide diuretics: increased incidence of thrombocytopenia with purpura in elderly patients 2
  • Methotrexate: concurrent use can cause severe toxicity 11

Key Clinical Pitfalls

The dose-dependent nature of adverse reactions means prophylactic dosing has lower reaction rates than therapeutic dosing 3. Adequate hydration is critical to prevent crystalluria 2. Monitor for hyperkalemia in patients with renal insufficiency, underlying potassium metabolism disorders, or those on medications that induce hyperkalemia 2. The recent FDA warning regarding acute respiratory failure in adolescents and young adults should prompt careful risk-benefit assessment in this age group 9.

References

10
Research

The Risks of Using Trimethoprim/Sulfamethoxazole in Patients with Renal and Cardiac Compromise.

Journal of the American Podiatric Medical Association, 2022

11
Guideline

guidelines of care for the management of acne vulgaris.

Journal of the American Academy of Dermatology, 2016

Related Questions

What are the adverse effects of trimethoprim-sulfamethoxazole (TMP‑SMX)?
Does trimethoprim‑sulfamethoxazole (Bactrim) treat kidney stones?
Can you prescribe Bactrim (trimethoprim‑sulfamethoxazole) for a patient with a creatinine clearance of 39 mL/min and a white blood cell count of 10.53 ×10⁹/L?
What oral antibiotics can I prescribe for a male patient who developed altered mental status from trimethoprim‑sulfamethoxazole (Bactrim)?
A patient tolerated trimethoprim‑sulfamethoxazole (Bactrim) for 8 days and then developed esophagitis‑like symptoms on day 9; what is the likely cause and how should it be managed?
What is the clinical significance of an ultrasound showing an atrophied ovary in a woman who had a cyst in that ovary three months ago and experienced a manually detorsed ovarian torsion six years ago?
What ICD-10-CM codes can be used for a skin tear on the left forearm after the patient reached to fix a swamp cooler, with the area cleaned, covered with a dry dressing, and the patient placed on prophylactic antibiotics?
What is the recommended management and follow‑up for a patient with mild posterior mitral valve fibrosis?
In an 82‑year‑old woman with severe anemia (hemoglobin 7.7 g/dL), what is the significance of a white‑blood‑cell count of 13.4 ×10⁹/L, platelet count of 351 ×10⁹/L, and macrocytic mean corpuscular volume of 103.2 fL, and how should she be managed?
In a 20‑week pregnant woman who experienced an electrical shock and has a normal fetal heart rate on initial monitoring, what further evaluation and management steps are recommended?
In a 30-year-old male with transverse myelitis who underwent multiple head and neck computed tomography scans (both non-contrast and contrast-enhanced), what is the statistical risk of developing radiation-induced brain cancer, what is the typical latency period for such tumors, and what are the current advances in glioblastoma treatment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.